CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Clinical trial NCT04653493 · UNKNOWN

Trial details

NCT number: NCT04653493
Sponsor: Sabz Biomedicals
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Start date: 2021-08-01
Primary completion: 2024-08-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.